Madeleine B Landau, Mohammad H Hussein, Marcela Herrera, Joshua Linhuber, Eman Toraih, Emad Kandil
{"title":"倾向分析揭示了基于手术的T1a和T1b高分化甲状腺癌的生存差异。","authors":"Madeleine B Landau, Mohammad H Hussein, Marcela Herrera, Joshua Linhuber, Eman Toraih, Emad Kandil","doi":"10.21037/gs-24-327","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>With rising well-differentiated thyroid cancer (WDTC) incidence, the appropriate treatment choice remains controversial for T1 tumors <2 cm. This study analyzed differences in surgery refusal and survival outcomes between T1a (<1 cm) and T1b (1-2 cm) WDTC, examining the demographic and clinical characteristics associated with patients who decide to either undergo or refuse recommended surgery.</p><p><strong>Methods: </strong>We studied 81,664 T1N0M0 WDTC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2000-2019]. Treatment with surgery (n=81,565) or refusal (n=99) was compared. Propensity score matching balanced groups. Cox models assessed mortality predictors.</p><p><strong>Results: </strong>Among 81,664 patients, the overall mortality rate was 5.7% (n=4,635 deaths). Refused surgery associated with higher mortality (11.1% <i>vs</i>. 5.7%, P=0.03) and shorter survival times (152.05±7.43 <i>vs</i>. 178.62±0.17 months, P<0.001). Thyroid cancer-specific mortality rates were 2.2% for refused surgery and 0.4% with surgery (P=0.01). Refusing surgery carried over twice the mortality risk [adjusted hazards ratio (aHR) =2.15, 95% confidence interval (CI): 1.01-4.57, P=0.046]. However, for T1b patients, refusing surgery escalated mortality risk over 3-fold (aHR =3.44, 95% CI: 1.43-8.28, P=0.006), yet for T1a patients it showed no increased risk (aHR =0.41, 95% CI: 0.049-3.46, P=0.42). Other independent risk factors for mortality included older age (aHR =6.24 for ≥55 years) and prior malignancy (aHR =2.78).</p><p><strong>Conclusions: </strong>Our study reveals notable differences in survival and mortality between T1a and T1b WDTC, underscoring the need for subtype-specific, evidence-based treatment guidelines. For T1b patients, surgery remains the standard of care with significant improvements in outcomes. In contrast, select T1a patients may benefit from active surveillance, offering comparable survival rates while potentially enhancing quality of life.</p>","PeriodicalId":12760,"journal":{"name":"Gland surgery","volume":"13 12","pages":"2335-2347"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733632/pdf/","citationCount":"0","resultStr":"{\"title\":\"Propensity analysis reveals survival disparities between T1a and T1b well-differentiated thyroid cancer based on surgery.\",\"authors\":\"Madeleine B Landau, Mohammad H Hussein, Marcela Herrera, Joshua Linhuber, Eman Toraih, Emad Kandil\",\"doi\":\"10.21037/gs-24-327\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>With rising well-differentiated thyroid cancer (WDTC) incidence, the appropriate treatment choice remains controversial for T1 tumors <2 cm. This study analyzed differences in surgery refusal and survival outcomes between T1a (<1 cm) and T1b (1-2 cm) WDTC, examining the demographic and clinical characteristics associated with patients who decide to either undergo or refuse recommended surgery.</p><p><strong>Methods: </strong>We studied 81,664 T1N0M0 WDTC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2000-2019]. Treatment with surgery (n=81,565) or refusal (n=99) was compared. Propensity score matching balanced groups. Cox models assessed mortality predictors.</p><p><strong>Results: </strong>Among 81,664 patients, the overall mortality rate was 5.7% (n=4,635 deaths). Refused surgery associated with higher mortality (11.1% <i>vs</i>. 5.7%, P=0.03) and shorter survival times (152.05±7.43 <i>vs</i>. 178.62±0.17 months, P<0.001). Thyroid cancer-specific mortality rates were 2.2% for refused surgery and 0.4% with surgery (P=0.01). Refusing surgery carried over twice the mortality risk [adjusted hazards ratio (aHR) =2.15, 95% confidence interval (CI): 1.01-4.57, P=0.046]. However, for T1b patients, refusing surgery escalated mortality risk over 3-fold (aHR =3.44, 95% CI: 1.43-8.28, P=0.006), yet for T1a patients it showed no increased risk (aHR =0.41, 95% CI: 0.049-3.46, P=0.42). Other independent risk factors for mortality included older age (aHR =6.24 for ≥55 years) and prior malignancy (aHR =2.78).</p><p><strong>Conclusions: </strong>Our study reveals notable differences in survival and mortality between T1a and T1b WDTC, underscoring the need for subtype-specific, evidence-based treatment guidelines. For T1b patients, surgery remains the standard of care with significant improvements in outcomes. In contrast, select T1a patients may benefit from active surveillance, offering comparable survival rates while potentially enhancing quality of life.</p>\",\"PeriodicalId\":12760,\"journal\":{\"name\":\"Gland surgery\",\"volume\":\"13 12\",\"pages\":\"2335-2347\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733632/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gland surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/gs-24-327\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gland surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/gs-24-327","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
背景:随着高分化甲状腺癌(WDTC)发病率的上升,T1肿瘤的适当治疗选择仍然存在争议。方法:我们在监测、流行病学和最终结果(SEER)登记处研究了81,664名T1N0M0 WDTC患者[2000-2019]。手术治疗(n=81,565)和拒绝治疗(n=99)进行比较。倾向得分匹配平衡组。Cox模型评估了死亡率预测因子。结果:81664例患者中,总死亡率为5.7% (n= 4635例死亡)。拒绝手术与更高的死亡率(11.1% vs. 5.7%, P=0.03)和更短的生存时间(152.05±7.43 vs. 178.62±0.17个月)相关。结论:我们的研究显示T1a和T1b WDTC的生存和死亡率存在显著差异,强调需要针对亚型特异性的循证治疗指南。对于T1b患者,手术仍然是标准的治疗方法,并能显著改善预后。相比之下,选择性T1a患者可能受益于主动监测,提供相当的生存率,同时潜在地提高生活质量。
Propensity analysis reveals survival disparities between T1a and T1b well-differentiated thyroid cancer based on surgery.
Background: With rising well-differentiated thyroid cancer (WDTC) incidence, the appropriate treatment choice remains controversial for T1 tumors <2 cm. This study analyzed differences in surgery refusal and survival outcomes between T1a (<1 cm) and T1b (1-2 cm) WDTC, examining the demographic and clinical characteristics associated with patients who decide to either undergo or refuse recommended surgery.
Methods: We studied 81,664 T1N0M0 WDTC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2000-2019]. Treatment with surgery (n=81,565) or refusal (n=99) was compared. Propensity score matching balanced groups. Cox models assessed mortality predictors.
Results: Among 81,664 patients, the overall mortality rate was 5.7% (n=4,635 deaths). Refused surgery associated with higher mortality (11.1% vs. 5.7%, P=0.03) and shorter survival times (152.05±7.43 vs. 178.62±0.17 months, P<0.001). Thyroid cancer-specific mortality rates were 2.2% for refused surgery and 0.4% with surgery (P=0.01). Refusing surgery carried over twice the mortality risk [adjusted hazards ratio (aHR) =2.15, 95% confidence interval (CI): 1.01-4.57, P=0.046]. However, for T1b patients, refusing surgery escalated mortality risk over 3-fold (aHR =3.44, 95% CI: 1.43-8.28, P=0.006), yet for T1a patients it showed no increased risk (aHR =0.41, 95% CI: 0.049-3.46, P=0.42). Other independent risk factors for mortality included older age (aHR =6.24 for ≥55 years) and prior malignancy (aHR =2.78).
Conclusions: Our study reveals notable differences in survival and mortality between T1a and T1b WDTC, underscoring the need for subtype-specific, evidence-based treatment guidelines. For T1b patients, surgery remains the standard of care with significant improvements in outcomes. In contrast, select T1a patients may benefit from active surveillance, offering comparable survival rates while potentially enhancing quality of life.
期刊介绍:
Gland Surgery (Gland Surg; GS, Print ISSN 2227-684X; Online ISSN 2227-8575) being indexed by PubMed/PubMed Central, is an open access, peer-review journal launched at May of 2012, published bio-monthly since February 2015.